report adj ep consensu due tax pharma compens
weak medic remain sidelin lower guidanc management guid modest
ep growth indic quick fix cordi despit market reaction less
concern commentari gener deflat given posit red oak comment
expect due tax
compani report thomson eikon cowen compani
report pharma rev y/i slightli expect
oper margin ahead expect sale
driven growth pharma specialti partial off-set expir prime
report adj ep y/i consensu
much higher expect tax rate caus miss tax come higher
expect without tax earn would
greater consensu unfavor tax rate due discret item
signific neg impact reduct cordi incom partial off-set
pharma revenu came y/i beat expect
oper profit y/i compar consensu revenu
driven pharmaceut specialti distribut custom partial off-set
expir larg mail-ord custom contract divestitur china
pleas see page report import disclosur
remain sidelin due issu cordi result downward
guidanc revis expect see model adj ep
growth could becom construct issu cordi resolv
profit medic stabil said underli fundament pharma
segment appear improv buy-sel gener deflat appear stabil
red oak perform ahead management expect
 addit details/progress red oak
 progress medic
 at-risk gener inflat
brand gener
 progress specialti
 integr acquisit
 gross margin pressur
 ebit margin
 top-lin growth high-singl digit
due better expect result
 top-lin growth low-single-digit
due weaker expect contribut
 gross margin closer greater
benefit red oak medic
 gross margin due weaker
expect gener profit
 sg come better oper
 restructur cost weigh
 share repo greater
one three largest pharmaceut distribut compani
 oper billion pharmaceut market compani distribut
comprehens offer brand-nam gener pharmaceut over-the-count
healthcar product home healthcar suppli equip wide varieti
healthcar provid locat throughout includ acut care hospit health
system independ chain retail pharmaci mail-ord facil physician clinic
alternate-sit facil cardin oper today two report segment
pharmaceut medic cardin recent focus home health space
medic revenu y/i miss consensu oper
profit y/i compar consensu miss oper
profit like due under-perform cordi lesser extent cardin
expect modest growth
management provid color regard variou put take notabl issu
cordi expect persist like advers impact tax
rate well number custom repric notabl
repric optum renew addit loss pharmerica anoth
headwind management also expect gener deflat continu result
headwind management expect modest adj ep growth well consensu
management lower adj ep guidanc revis
guidanc metric includ effect tax rate dilut
weight averag share
pharma segment oper profit guidanc revis high-singl low-
doubl digit low-doubl digit within key assumpt management revis gener
drug price assumpt mid- high-singl digit deflat mid-singl digit
deflat better expect increment contribut red oak sourc
medic segment oper profit guidanc strong double-digit growth maintain
howev within key assumpt management revis segment profit growth expect
ex-pati recoveri high-teen flat primarili due cordi also
management expect second-half segment profit margin rate reach primarili
due cordi
invest thesi remain larg intact issu medic segment
persist expect although greater degre howev note
current issu cordi stem inventori reserv result greater
visibl inventori newli implement inventori manag system
seem one-tim natur although could see addit inventori reserv
adjust anoth coupl quarter anniversari
see profit rebound higher stabl level patient recoveri acquisit
howev perform ahead management expect said even past inventori
adjust issu seem clear still process issu need work
demand forecast input cost management etc take addit time see cordi
remain overhang clear resolut least near term believ
market perform rate appropri
bright side underli fundament pharma segment seem improv
despit revis gener sell-sid deflat mid- high-singl digit deflat
mid-singl digit deflat factor sell-sid price out-performance
red oak appear offset greater sell-sid deflat
emphas net margin sell-sid buy-sid deflat reflect
profit gener sole sell- buy-sid deflat furthermor although
renew optum contract near-term headwind anniversari price
stabl recent extend expand agreement expir
updat estim price target
lower adj ep estim
respect also lower price target base revis
dcf analysi note rais discount rate result cordi price target
impli share trade adj ep estim current
valuat
million except per-shar data
cowen compani
model assumptionstermin growth tax depreci chang work terminal- capit valuefre pv npv free npv futur excess valu total number valu per fiscal year end june cowen
million except per-shar data
compani report cowen compani
good gross gross chang sell gener oper interest pre-tax incom tax incom continu net incom deal-rel discontinu operations- non-recurring net incom dilut weight averag ep continu ep chang year-over-year oper incom continu continu year end june cowen
million except per-shar data
compani report cowen compani
good gross gross chang sell gener oper interest pre-tax pre-tax incom tax net earn attribut non-controlling net incom continu net incom deal-rel discontinu operations- non-recurring net incom dilut weight averag adj chang year-over-year oper incom continu continu cowen
million
compani report cowen compani
asset trade receiv merchandis prepaid expens current pp goodwil total current liabil current portion long-term account accru current long-term defer tax redeem non-controlling interest- stockhold equiti common retain common share cumul foreign currenc non-controlling interests- total stockhold total liabil stockhold short-term liquid ratio current sale day purchas account inventori ratio inventori capit structur long-term solvenc ratio total debt total interest ratio return invest capit averag total asset averag stockhold equiti year end june cowen
million
compani report cowen compani
income/ loss cumul effect chang accounting- earn /loss discontinu operations- earn cont op b/f effect chg flow oper activ depreci sale provis loss account charg reorg busi charges- sale invest businesses- employe stock defer incom invest impair chang oper asset liabil account merchandis prepaid expens assets- account oper net cash use /provid op activ disc ops- net cash oper acquisit properti acquisit issuanc common purchas treasuri dividend common proceeds/ purchas secur proceeds/ repay debt net increase/ decreas cash equival begin cash equival end cowen summari capit owner financ non-recur year end june cowen
million
compani report cowen compani
flow oper activitiesnet cumul effect chang accounting- earn /loss discontinu earn cont op cumul effect chang adjust reconcil net earn net cash depreci sale investments- asset loss debt extinguishment- sale carefus common stock- purchas in-process d- equiti provis defer incom tax provis bad debt chang fair valu conting consider oblig chang oper asset liabil net increas trade receiv increas increas net invest sales-typ leases- increas account oper item net net cash use /provid oper activ discontinu ops- net cash provid oper flow invest activ acquisition/divestitur subsidiari net cash acquir proce sale properti equip addit properti equip sale/ purchas market secur avail sale proce matur available-for-sal securities- proce divestitur dispos held sale assets- proce sale carefus common stock- net cash use /provid invest activ discontinu ops- net cash use invest flow financ activ payment conting consideration- net chang commerci paper short-term debt reduct long-term oblig net purchas non-controlling interests- proce interest rate swap terminations- proce long-term oblig net issuanc cost proce securit borrow payment premium debt extinguishment- proce issuanc common share tax benefit exercis stock purchas treasuri share net cash use /provid financ activ discontinu ops- net cash provid by/ use financ effect exchang rate chang cash equivalents- net increas decreas chang fiscal year equival begin equival end fiscal year end june cowen
use five-year discount cash flow analysi primari valuat method
deriv price target gener assum discount rate may appli
appropri adjust depend compani and/or industri specif factor also
assum termin growth rate depend long-term view specif
sub-industri coverag note discount rate assumpt could view
conserv rel actual weight averag cost capit view
assumpt reason long run lower discount rate assumpt
increas termin growth rate assumpt would lead higher estim valu
per share secondari measur look forward price-to-earnings multipl ev/sal ratio
impli dcf analysi compar histor averag
potenti risk associ drug distribut space industri
highli competit could pressur margin core drug distribut busi
current wave drug patent expir posit impact profit
deriv gener expect taper significantli next sever year
specialti provid signific tailwind industri concern
around sustain high growth biotech sector longer term
impact ppaca expect increas volum could subdu depend
implement execut
number company-specif risk associ pt includ
abil turn around medic segment integr risk relat cordi patient
recoveri manag abil deploy capit effect faster-than-
expect turnaround cordi
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock secur
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
